OT

Outlook Therapeutics IncNASDAQ OTLK Stock Report

Last reporting period 31 Dec, 2023

Updated 18 Nov, 2024

Last price

Market cap $B

0.132

Micro

Exchange

XNAS - Nasdaq

OTLK Stock Analysis

OT

Uncovered

Outlook Therapeutics Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.132

Dividend yield

Shares outstanding

256.67 B

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 17 full-time employees. The company went IPO on 2016-06-13. The firm focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. The firm's product candidate, ONS-5010, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab is a full-length, humanized anti- Vascular Endothelial Growth Factor (VEGF) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. VEGF is a protein that promotes the growth of new abnormal blood vessels. Its biologics license application (BLA) for ONS-5010 in wet AMD involved three clinical trials, which include NORSE ONE, NORSE TWO and NORSE THREE. The firm sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets.

View Section: Eyestock Rating